Skip to main content

Table 3 BWS conditional logistic regression

From: Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best–worst scaling experiment in caregivers and adult patients

Object   95% CI  
B SE B OR LL UL P
Chance of improved muscle functiona 0.00 1.00
Chance of improved lung function −0.14 0.18 0.87 0.61 1.25 .450
Limits later use of gene therapy or CRISPR −0.26 0.12 0.77 0.61 0.98 .033
Chance of improved heart function −0.28 0.08 0.75 0.65 0.87 <.001
Chance of death (low risk) −0.84 0.13 0.43 0.34 0.56 <.001
Lowest dose may be too low for benefit −1.20 0.12 0.30 0.24 0.38 <.001
Become ineligible for future trials −1.20 0.13 0.30 0.23 0.39 <.001
Benefit lasts about 10 years −1.32 0.09 0.27 0.23 0.32 <.001
Chance of long hospitalization −1.75 0.11 0.17 0.14 0.22 <.001
Chance of being in placebo group −1.98 0.12 0.14 0.11 0.17 <.001
Two muscle biopsies required −2.49 0.11 0.08 0.07 0.10 <.001
Interaction terms
 Improved lung function × Adults with Duchennea
 Improved lung function × Parents of children who walk −0.94 0.19 0.39 0.27 0.57 <.001
 Improved lung function × Parents of children who use a wheelchair −0.32 0.20 0.72 0.49 1.08 .115
  1. N = 274. Wald χ2 (12)=741.24, P < .001, R2McFadden’s = .13. B = Conditional logit regression coefficient. SE B = Robust standard error of B. OR = Odds ratio. CI = Confidence interval for odds ratios. LL = Lower limit of confidence interval. UL = Upper limit of confidence interval
  2. aReference category